Evaluation of Continuous Glucose Monitoring in Participants With Type 2 Diabetes Mellitus (MK-0000-258 AM2)
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This trial will attempt to develop the use of Continuous Glucose Monitoring (CGM) as a tool
for the evaluation of both new and existing pharmacological treatments for type 2 diabetes,
using the twice daily administered dipeptidyl peptidase-4 (DPP4) inhibitor, vildagliptin as a
probe. The primary hypothesis is that two weeks of treatment with 50 mg of oral Vildagliptin,
twice daily will lead to a statistically significant decrease in 24 hour weighted-mean
glucose (WMG) relative to placebo.